Parkman Healthcare Partners’s Eli Lilly LLY Stock Holding History

Parkman Healthcare Partners’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$31.8M	Buy	+34,616	New	+$35.1M	3.28%	5
2025 Q4	–	Sell	-10,000	Closed	-$7.63M	–	106
2025 Q3	$7.63M	Sell	10,000 -23,296	-70%	-$17.3M	0.8%	48
2025 Q2	$26M	Sell	33,296 -5,895	-15%	-$4.58M	2.98%	7
2025 Q1	$32.4M	Buy	39,191 +11,028	+39%	+$9.18M	3.84%	3
2024 Q4	$21.7M	Sell	28,163 -12,221	-30%	-$10.1M	2.9%	7
2024 Q3	$35.8M	Buy	40,384 +8,730	+28%	+$7.85M	4.57%	3
2024 Q2	$28.7M	Sell	31,654 -463	-1%	-$370K	3.84%	4
2024 Q1	$25M	Buy	+32,117	New	+$22.9M	3.07%	6
2023 Q2	–	Sell	-27,671	Closed	-$9.5M	–	101
2023 Q1	$9.5M	Sell	27,671 -6,767	-20%	-$2.28M	2.07%	15
2022 Q4	$12.6M	Sell	34,438 -847	-2%	-$300K	3.35%	5
2022 Q3	$11.4M	Buy	+35,285	New	+$11.2M	3.24%	6

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Parkman Healthcare Partners's LLY Position: Q1 2026 in Review

Parkman Healthcare Partners opened a new position in Eli Lilly (LLY) in Q1 2026: 34,616 shares worth $31.8M. The stake represents 3.28% of the portfolio and ranks #5 among its holdings. This is a return to the name: Parkman Healthcare Partners previously reported a position in LLY as recently as Q3 2025.

Parkman Healthcare Partners first reported a position in LLY in Q3 2022 and has held it in 11 quarters since. The position peaked at $35.8M in Q3 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Parkman Healthcare Partners held 34,616 shares of Eli Lilly worth $31.8M as of Q1 2026.
Eli Lilly was a new Parkman Healthcare Partners position in Q1 2026.
Eli Lilly made up 3.28% of Parkman Healthcare Partners's portfolio in Q1 2026, its #5 holding.
Parkman Healthcare Partners first reported a position in Eli Lilly in Q3 2022 and has held it in 11 quarters since.
Parkman Healthcare Partners's Eli Lilly position peaked at $35.8M in Q3 2024.
4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.